Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema

Eli Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) are marching forward in their quest to gain regulatory approval for Olumiant as a treatment for atopic dermatitis (AD), commonly referred to as eczema.